In this study, the predictive value of MIRS in breast cancer patients who received adjuvant chemotherapy was examined. Kaplan-Meier curves displayed that the breast cancer patients with the low MIRS subtype had much better survival than those with the high MIRS subtype in adjuvant chemotherapy cases. Similarly, without adjuvant chemotherapy, the patients with the high MIRS subtype had significantly decreased survival when compared with those with the low MIRS subtype. We also verified the effectiveness of MIRS in predicting the response of immunotherapy for breast cancer patients using the T-cell inflammatory signature(TIS) indicator.